Literature DB >> 15864388

Irinotecan-induced colitis.

D Sandmeier1, P Chaubert, H Bouzourene.   

Abstract

Irinotecan (CPT-11) is a chemotherapeutic drug used to treat tumors by acting on malignant cells through inhibition of DNA topoisomerase I and inducing premature apoptosis. Major toxic effects of Irinotecan are myelosuppression and gastrointestinal (GI) toxicity, which limits the dose of administration, particularly severe diarrhea with a delay of onset. However, according to the literature, serious GI side effects are uncommon, comprising 3% of the reported cases. The mechanism of Irinotecan-induced delayed diarrhea is unknown and unpredictable. To our knowledge, this is the first case of colitis associated with Irinotecan administration for temporal glioblastoma documented by biopsies. The histopathologic findings are described and the potential mechanisms inducing such lesions are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864388     DOI: 10.1177/106689690501300215

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  9 in total

1.  Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.

Authors:  Yujiro Fujie; Masataka Ikeda; Iwao Seshimo; Koji Ezumi; Taishi Hata; Tatsushi Shingai; Masayoshi Yasui; Osamu Takayama; Hiroki Fukunaga; Masakazu Ikenaga; Ichiro Takemasa; Hirofumi Yamamoto; Masayuki Ohue; Mitsugu Sekimoto; Seiichi Hirota; Morito Monden
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

2.  Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Authors:  Chuyao Liao; Di Wang; Siyuan Qin; Ying Zhang; Jie Chen; Ruijie Xu; Fengguo Xu; Pei Zhang
Journal:  Front Pharmacol       Date:  2022-05-31       Impact factor: 5.988

3.  Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin.

Authors:  David Kung; Daniel T Ruan; Rodney K Chan; Melissa L Ericsson; Mandeep S Saund
Journal:  Dig Dis Sci       Date:  2007-05-26       Impact factor: 3.199

4.  Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

Authors:  Vinay K Puduvalli; Pierre Giglio; Morris D Groves; Kenneth R Hess; Mark R Gilbert; Srikanth Mahankali; Edward F Jackson; Victor A Levin; Charles A Conrad; Sigmund H Hsu; Howard Colman; John F de Groot; Melesa G Ritterhouse; Sandra E Ictech; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2008-02-26       Impact factor: 12.300

5.  Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.

Authors:  François Ghiringhelli; Julie Vincent; Françoise Beltjens; Leila Bengrine; Sylvain Ladoire
Journal:  Invest New Drugs       Date:  2015-10-22       Impact factor: 3.850

6.  No relation between docetaxel administration route and high-grade diarrhea incidence.

Authors:  Jeroen J M A Hendrikx; Frederik E Stuurman; Ji-Ying Song; Vincent A de Weger; Jurjen S Lagas; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel; Jan H M Schellens; Serena Marchetti
Journal:  Pharmacol Res Perspect       Date:  2020-08

7.  Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis.

Authors:  Michael Thomsen; Luis Vitetta
Journal:  Integr Cancer Ther       Date:  2018-08-23       Impact factor: 3.279

Review 8.  Decoding inflammation, its causes, genomic responses, and emerging countermeasures.

Authors:  Jacek Hawiger; Jozef Zienkiewicz
Journal:  Scand J Immunol       Date:  2019-08-28       Impact factor: 3.487

9.  The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.

Authors:  Graham Skelhorne-Gross; Christopher J B Nicol
Journal:  PPAR Res       Date:  2012-07-02       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.